269 related articles for article (PubMed ID: 28800944)
1. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Fortner RT; Damms-Machado A; Kaaks R
Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
4. A novel algorithm to improve specificity in ovarian cancer detection.
Arjomandi A; Delanoy ML; Walker RP; Binder SR
Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
6. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
Shi JX; Qin JJ; Ye H; Wang P; Wang KJ; Zhang JY
Expert Rev Mol Diagn; 2015 Jun; 15(6):829-52. PubMed ID: 25959246
[TBL] [Abstract][Full Text] [Related]
7. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
8. [Screening and sero-immunoscreening of ovarian epithelial cancer associative antigens].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2007 Dec; 42(12):834-9. PubMed ID: 18476518
[TBL] [Abstract][Full Text] [Related]
9. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
10. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
11. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
12. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
Garziera M; Montico M; Bidoli E; Scalone S; Sorio R; Giorda G; Lucia E; Toffoli G
PLoS One; 2015; 10(10):e0140351. PubMed ID: 26451959
[TBL] [Abstract][Full Text] [Related]
14. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
15. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
17. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.
Gupta P; Suman S; Mishra M; Mishra S; Srivastava N; Kumar V; Singh PK; Shukla Y
Proteomics Clin Appl; 2016 May; 10(5):564-73. PubMed ID: 27068564
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer.
Ouyang R; Wu S; Zhang B; Wang T; Yin B; Huang J; Wei W; Huang M; Zhang M; Wang Y; Wang F; Hou H
Cancer Biomark; 2021; 32(3):401-409. PubMed ID: 34151844
[TBL] [Abstract][Full Text] [Related]
20. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
